Buzz
The FDA has recently approved a 'modified risk' designation for a specific snus brand, a Swedish tobacco product gaining popularity in the US. While it may pose fewer risks than other tobacco forms, it is not entirely risk-free.
Snus (pronounced like 'goose') is packaged in small pouches designed to be placed between the upper lip and gums. Unlike chewing tobacco or dip, it doesn't produce excessive saliva, eliminating the need for frequent spitting.
All forms of oral or 'smokeless' tobacco products come with cancer risks. While lung cancer isn't a concern since no smoke is inhaled, users of smokeless tobacco face increased risks of mouth, throat, tongue, pancreatic, and esophageal cancers.
Snus presents a reduced risk for certain cancers compared to other tobacco products. If a smoker quits cigarettes and fully switches to snus, their risk of developing these cancers decreases. After Swedish Match, the snus manufacturer, provided evidence supporting this claim, the FDA permitted the company to include the following statement on its labels: “Switching from cigarettes to General Snus lowers your risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
This marks the first instance the FDA has awarded modified-risk status to a tobacco product. However, the agency’s press release clarifies that this does not imply snus is 'safe.' The product must still display standard smokeless tobacco warnings, such as 'WARNING: This product can cause mouth cancer.' Acting FDA Commissioner Ned Sharpless encapsulated the agency’s stance:
Although we are approving these specific modified-risk tobacco products, it’s crucial for the public to recognize that all tobacco products — including these — carry risks. Individuals who do not currently use tobacco products, particularly youth, should avoid starting.
